InsidersTradesSigma
Total declarations
Companies
▲ Purchases (0 ops.)
▼ Sales (9 ops.)
Insider track record
CFODisclosed buys
0
Disclosed sells
9
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
Explore the detailed record of transactions filed by Myszkowski Kenneth Allen, Chief Financial Officer. Insider active across 2 companies, notably Arrowhead Pharmaceuticals, INC.. In total, 16 reports have been recorded. Breakdown: 0 buy · 9 sells. Total volume traded: €4.7m. Activity tracked since 1 January 2022. The latest transaction was filed on 6 January 2025 (Cession). Regulator: SEC (Form 4). All data is openly available.
Companies and markets linked to Myszkowski Kenneth Allen
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations16 total
17,765 shares@ US$19.686.2% of flowCommon StockSEC:0001628280-25-000805:1
9,402 shares@ US$20.103.3% of flowCommon StockSEC:0001628280-25-000805:2
8,000 shares@ US$19.702.8% of flowCommon StockSEC:0001628280-25-000805:3
10,000 shares@ US$19.693.4% of flowCommon StockSEC:0001628280-25-000805:4
100,000 shares0Common StockSEC:0001628280-25-000805:0
40,000 shares@ US$35.1923.5% of flowCommon StockSEC:0001628280-24-010062:0
75,000 shares0Common StockSEC:0001628280-24-000866:0
15,000 shares@ US$36.209.0% of flowCommon StockSEC:0001628280-23-023950:0
60,000 shares0Common StockSEC:0001209191-23-002116:0
30,625 shares@ US$40.0020.9% of flowCommon StockSEC:0001209191-22-063020:0
15,908 shares@ US$60.5018.3% of flowCommon StockSEC:0001209191-22-002290:0
60,000 shares0Common StockSEC:0001209191-22-001299:0
13,048 sharesCommon StockSEC:0001209191-16-097060:0
13,153 sharesCommon StockSEC:0001209191-16-088041:0
23,347 sharesCommon StockSEC:0001209191-16-088041:1
50,000 sharesCommon StockSEC:0001209191-16-088041:2
16 of 16 declarations
About Myszkowski Kenneth Allen
Kenneth Allen Myszkowski is Chief Financial Officer. The 16 filings on record, all of the sampled filings available, concern sales at Arrowhead Pharmaceuticals, INC. and ARROWHEAD RESEARCH CORP, with EUR 0 in buys and EUR 4,661,551 in sells over the period from 2016-01-04 to 2025-01-07.
